David E. Cohn, MD
Professor
The Ohio State University
320 West 10th Avenue
M-210 Starling Loving Hall
Columbus,
OH
USA
43210
Biographical Sketch: I direct the division of a PPS-exempt cancer hospital, and am a member of the SGO Quality and Outcomes Committee"
Papers:
6
Clinical implications for MSI, MLH1 methylation analysis and IHC in Lynch screening for endometrial cancer patients: an analysis of 940 endometrioid endometrial cancer cases from the GOG0210 study
54
A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy
89
Adherence to a standard algorithm results in high negative predictive value of sentinel lymph node assessment using indocyanine green (ICG) and isosulfane blue (ISB) dye in endometrial cancer
94
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center (CCC)
95
The use of NCCN guideline therapy in the first line/adjuvant setting in patients with ovarian cancer from 6 NCCN Institutions
208
Outcomes in stage III endometrial cancer are similar for chemotherapy +/- radiation in low and high risk histology
364
Outpatient rapid desensitization for gynecologic oncology patients with moderate to severe hypersensitivity reactions to platinums
427
Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer
502
Suppression of ovarian cancer growth and metastasis with HO-3867, a STAT3 inhibitor, in human tissue culture and in an orthotopic mouse model
503
Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and HO-4318, in ovarian cancer
511
Unveiling novel mutations in the DNA-binding domain of FOXA2 in endometrioid endometrial cancers
Introductory Remarks
Concluding Remarks